AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11991284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose local nasal immunotherapy (LNIT) with a build-up phase from 2.5 AU to 80 AU and maintenance at 80 AU once a week
Number of subjects: 32
Study 11991284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10209659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychological treatment (education, relaxation, breathing training, graded exposure to activity and exercise, challenging automatic thoughts about heart disease)
Number of subjects: 60
Study 10209659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychological treatment
Number of subjects: 60
Study 10209659 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study 8531509 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg DL-oxyfedrine*HCl tablets
Number of subjects: 12
Study 8531509 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 mg DL-oxyfedrine*HCl tablets
Number of subjects: 12
Study 8531509 — intervention group
Group type: COMPARATOR
Intervention: Equimolar aqueous solution of DL-oxyfedrine*HCl
Number of subjects: 12
Study 2625270 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked group (140 patients) - lymphatic tissue of the axilla marked by technetium‐99 antimonsulfide and operated on a gammacamera
Number of subjects: 264
Study 2625270 — intervention group
Group type: COMPARATOR
Intervention: Unmarked group (124 patients) - no marking of lymphatic tissue
Number of subjects: 264
Study 2625270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 264
Study 29720097 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively autonomous physical activity (PAPA) program
Number of subjects: 47
Study 29720097 — intervention group
Group type: COMPARATOR
Intervention: Supervised physical activity (SPA) program
Number of subjects: 47
Study 26272050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 97
Study 26272050 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 97
Study 26240500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal body weight
Number of subjects: 100
Study 26240500 — intervention group
Group type: COMPARATOR
Intervention: Actual body weight
Number of subjects: 100
Study 23471549 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH + letrozole (2.5 mg on days 3-7 of the menstrual cycle)
Number of subjects: 40
Study 23471549 — intervention group
Group type: COMPARATOR
Intervention: rFSH alone (starting on day 3)
Number of subjects: 40
Study 21029314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical thermochemotherapy (Synergo®)
Number of subjects: 83
Study 21029314 — intervention group
Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone (mitomycin-C)
Number of subjects: 83
Study 19441888 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol
Number of subjects: 232
Study 19441888 — intervention group
Group type: COMPARATOR
Intervention: Timolol alone
Number of subjects: 232
Study 16571908 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related functional MRI (fMRI)
Number of subjects: 0
Study 14616151 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 717
Study 14616151 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 717
Study 14616151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 10890540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotripsy (maximum of 4 sessions, up to 3000 shocks/session, no anaesthesia or analgesia)
Number of subjects: 144
Study 10890540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy (elective open under general anaesthesia)
Number of subjects: 144
Study 10890540 — intervention group
Group type: COMPARATOR
Intervention: Crossover group (patients who underwent cholecystectomy after lithotripsy)
Number of subjects: 144
Study 9314638 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 103
Study 9314638 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 103
Study 8375130 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg desipramine
Number of subjects: 10
Study 8375130 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg fluvoxamine
Number of subjects: 10
Study 8375130 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg moclobemide
Number of subjects: 10
Study 8375130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3522157 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim (400 mg loading dose followed by 200 mg for 10 days)
Number of subjects: 60
Study 3522157 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (200 mg loading dose followed by 100 mg for 10 days)
Number of subjects: 60
Study 28960257 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth mindset intervention (n = 115)
Number of subjects: 222
Study 28960257 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control programme (n = 107)
Number of subjects: 222
Study 27552274 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement Program (CEP)
Number of subjects: 595
Study 27552274 — intervention group
Group type: COMPARATOR
Intervention: Technical Assistance (Resources for Services, RS)
Number of subjects: 595
Study 25011605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 5 weeks
Number of subjects: 26
Study 25011605 — intervention group
Group type: COMPARATOR
Intervention: North American isoenergetic control diet for 5 weeks
Number of subjects: 26
Study 22203318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-oriented therapy
Number of subjects: 0
Study 22203318 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction support group
Number of subjects: 0
Study 22203318 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-dependent patients who relapsed
Number of subjects: 0
Study 20691832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab treatment
Number of subjects: 64
Study 18294109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg administered as a 2-minute intravenous bolus injection
Number of subjects: 38
Study 18294109 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg administered as a 30-minute continuous infusion
Number of subjects: 38
Study 18294109 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) administered as an intravenous injection over 2 minutes
Number of subjects: 38
Study 17138081 — intervention group
Group type: EXPERIMENTAL
Intervention: Allon ThermoWrapping Thermoregulation System (study group, n = 15)
Number of subjects: 31
Study 17138081 — intervention group
Group type: COMPARATOR
Intervention: Forced-air system (Bair Hugger, control group, n = 16)
Number of subjects: 31
Study 12626998 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (5 ng x kg(‐1) x min(‐1)) plus unfractionated heparin
Number of subjects: 24
Study 12626998 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 24
Study 12626998 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin plus unfractionated heparin
Number of subjects: 24
Study 11076347 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term topical steroid therapy (6 months)
Number of subjects: 207
Study 11076347 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term topical steroid therapy (12 months)
Number of subjects: 207
Study 11076347 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic and local steroids treatment
Number of subjects: 207
Study 9299905 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock anticipation (threat-of-shock experiment)
Number of subjects: 0
Study 9299905 — intervention group
Group type: COMPARATOR
Intervention: Attention to external stimuli (control experiment)
Number of subjects: 0
Study 8382824 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study 8382824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibenelast
Number of subjects: 0
Study 8382824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3539033 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic cream
Number of subjects: 15
Study 3539033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31759938 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks for 6 weeks
Number of subjects: 39
Study 31759938 — intervention group
Group type: COMPARATOR
Intervention: Lipoprotein apheresis (LA)
Number of subjects: 39
Study 26777257 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimode Comprehensive Tailored Information Package (MCTIP)
Number of subjects: 31
Study 26777257 — intervention group
Group type: COMPARATOR
Intervention: Ad hoc information provision (Control)
Number of subjects: 31
Study 25692612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged bivalirudin infusion
Number of subjects: 160
Study 25692612 — intervention group
Group type: COMPARATOR
Intervention: Standard bivalirudin treatment
Number of subjects: 160
Study 23831264 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (300mg)
Number of subjects: 0
Study 23831264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21992961 — intervention group
Group type: EXPERIMENTAL
Intervention: CS with bladder flap formation (BFF)
Number of subjects: 115
Study 21992961 — intervention group
Group type: COMPARATOR
Intervention: CS without bladder flap formation (BFF)
Number of subjects: 115
Study 19347349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 12
Study 19347349 — intervention group
Group type: COMPARATOR
Intervention: Control (macula hole or membrane)
Number of subjects: 12
Study 19347349 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVO
Number of subjects: 12
Study 16762754 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK)
Number of subjects: 41
Study 16762754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD)
Number of subjects: 41
Study 15245597 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of 9 capsules of green tea extract powder per day (equivalent to 10 cups of regular green tea) for 5 months
Number of subjects: 83
Study 15245597 — intervention group
Group type: COMPARATOR
Intervention: No intake of green tea capsules (control group)
Number of subjects: 83
Study 11688594 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and progesterone replacement therapy for 6 weeks postnatally
Number of subjects: 30
Study 11688594 — intervention group
Group type: COMPARATOR
Intervention: Untreated infants (controls)
Number of subjects: 30
Study 9136939 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan/prednisone + interferon alpha‐2b
Number of subjects: 0
Study 9136939 — intervention group
Group type: COMPARATOR
Intervention: melphalan/prednisone
Number of subjects: 0
Study 8226554 — intervention group
Group type: EXPERIMENTAL
Intervention: Air with dead space (AVD)
Number of subjects: 9
Study 8226554 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 with dead space (O2VD)
Number of subjects: 9
Study 8226554 — intervention group
Group type: COMPARATOR
Intervention: Air control (AC)
Number of subjects: 9
Study 8226554 — intervention group
Group type: COMPARATOR
Intervention: 100% O2 control (O2C)
Number of subjects: 9
Study 3693764 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exclusion diet (cow's milk and egg)
Number of subjects: 212
Study 3693764 — intervention group
Group type: COMPARATOR
Intervention: Nondiet (control group)
Number of subjects: 212
Study 29713403 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal trigger point injections with prilocaine, home exercise program, and oral medications
Number of subjects: 65
Study 29713403 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program and oral medications
Number of subjects: 65
Study 27320846 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea polyphenols (GTP) containing 800 mg of epigallocatechin gallate
Number of subjects: 42
Study 27320846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25469706 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral STN DBS
Number of subjects: 30
Study 25469706 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral GPi DBS
Number of subjects: 30
Study 25469706 — intervention group
Group type: COMPARATOR
Intervention: Combined STN and GPi groups
Number of subjects: 30
Study 22650140 — intervention group
Group type: EXPERIMENTAL
Intervention: New percutaneous absorption herbal patch
Number of subjects: 120
Study 22650140 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional medicinal herbs cake
Number of subjects: 120
Study 22650140 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Accuhaler)
Number of subjects: 120
Study 22650140 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 22650140 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine patch and medicinal vesiculation groups
Number of subjects: 120
Study 22650140 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine patch group
Number of subjects: 120
Study 20148791 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based prevention programme (Climate Schools: Alcohol and Cannabis Course)
Number of subjects: 764
Study 20148791 — intervention group
Group type: COMPARATOR
Intervention: Usual health classes (Control group)
Number of subjects: 764
Study 18276061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10mg/kg) and Docetaxel (60mg/m²) every 3 weeks
Number of subjects: 20
Study 16509282 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler sonography on day 1 of the menstrual cycle
Number of subjects: 40
Study 16509282 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler sonography on day 15 of the menstrual cycle
Number of subjects: 40
Study 12445591 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention videotape on dieting and body image (n = 104)
Number of subjects: 218
Study 12445591 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n = 114)
Number of subjects: 218
Study 10850304 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Tumor (WT) vaccine
Number of subjects: 28
Study 10850304 — intervention group
Group type: EXPERIMENTAL
Intervention: TC vaccine (derived from IIB-MEL-J cells)
Number of subjects: 28
Study 10850304 — intervention group
Group type: COMPARATOR
Intervention: No immunotherapy (control group)
Number of subjects: 28
Study 8789216 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive glove on normal skin 6 h/day for 3 days
Number of subjects: 40
Study 8789216 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive glove on SLS-compromised skin 6 h/day for 3 days
Number of subjects: 40
Study 2018207 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100% O2 during MCH challenge
Number of subjects: 19
Study 2018207 — intervention group
Group type: COMPARATOR
Intervention: Breathing 21% O2 during MCH challenge
Number of subjects: 19
Study 2018207 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic patients breathing 100% O2 during MCH challenge
Number of subjects: 19
Study 2018207 — intervention group
Group type: COMPARATOR
Intervention: Asthmatic patients breathing 21% O2 during MCH challenge
Number of subjects: 19
Study 7178914 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation program for elderly
Number of subjects: 0
Study 7178914 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30554748 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP group A (threshold of 20 mg/L)
Number of subjects: 2410
Study 30554748 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP group B (threshold of 40 mg/L)
Number of subjects: 2410
Study 30554748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2410
Study 30554748 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP group B vs control group
Number of subjects: 2410
Study 30554748 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP group A vs control group
Number of subjects: 2410
Study 30554748 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP group A (CRP <20 mg/L)
Number of subjects: 2410
Study 30554748 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP group B (CRP <40 mg/L)
Number of subjects: 2410
Study 30562293 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered 3-item questionnaire (3IQ)
Number of subjects: 227
Study 30562293 — intervention group
Group type: COMPARATOR
Intervention: No change to wait-list priority (Control)
Number of subjects: 227
Study 26752586 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Start REDI intervention
Number of subjects: 356
Study 26752586 — intervention group
Group type: COMPARATOR
Intervention: Head Start as usual (control)
Number of subjects: 356
Study 24132660 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/fibre diet
Number of subjects: 45
Study 24132660 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet
Number of subjects: 45
Study 24132660 — intervention group
Group type: COMPARATOR
Intervention: Supervised low-volume aerobic training
Number of subjects: 45
Study 22344554 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly dissolving levetiracetam minitablets (1000 mg)
Number of subjects: 16
Study 22344554 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly dissolving levetiracetam minitablets (1500 mg)
Number of subjects: 16
Study 22344554 — intervention group
Group type: COMPARATOR
Intervention: Single-unit film-coated originator tablets (1000 mg)
Number of subjects: 16
Study 22344554 — intervention group
Group type: COMPARATOR
Intervention: Single-unit film-coated originator tablets (1500 mg)
Number of subjects: 16
Study 20171332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Binge Eating Disorder (DBT‐BED)
Number of subjects: 101
Study 20171332 — intervention group
Group type: COMPARATOR
Intervention: Active Comparison Group Therapy (ACGT)
Number of subjects: 101
Study 16895621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 15 mg kg‐1
Number of subjects: 40
Study 16895621 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meperidine 1 mg kg‐1
Number of subjects: 40
Study 16376774 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 45
Study 16376774 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic impairment
Number of subjects: 45
Study 16376774 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal impairment
Number of subjects: 45
Study 12461475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycasin HBC
Number of subjects: 12
Study 12461475 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 12
Study 10522990 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg aldosterone
Number of subjects: 12
Study 10522990 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg aldosterone
Number of subjects: 12
Study 10522990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7747707 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE plus UFT (tegafur 200 mg and uracil 448 mg per day)
Number of subjects: 40
Study 7747707 — intervention group
Group type: COMPARATOR
Intervention: TAE alone
Number of subjects: 40
Study 7747707 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE plus UFT
Number of subjects: 40
Study 1674230 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate hydrochloride 75 mg at 9 PM
Number of subjects: 192
Study 1674230 — intervention group
Group type: COMPARATOR
Intervention: untreated control group
Number of subjects: 192
Study 1674230 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate hydrochloride
Number of subjects: 192
Study 7352689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 23
Study 7352689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine
Number of subjects: 23
Study 7352689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30867551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (2 mg)
Number of subjects: 14
Study 30867551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (4 mg)
Number of subjects: 14
Study 30867551 — intervention group
Group type: COMPARATOR
Intervention: Intranasal naloxone (2 mg and 4 mg)
Number of subjects: 14
Study 28083711 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment (first-line)
Number of subjects: 1494
Study 28083711 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcript type e13a2
Number of subjects: 1494
Study 26503383 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided e-learning intervention for managers on work-related stress
Number of subjects: 424
Study 26503383 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 424
Study 26503383 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided e-learning intervention for managers
Number of subjects: 424
Study 23391763 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery and rt‐PA
Number of subjects: 118
Study 23391763 — intervention group
Group type: COMPARATOR
Intervention: Surgical aspiration and rt‐PA
Number of subjects: 118
Study 23391763 — intervention group
Group type: COMPARATOR
Intervention: Surgical aspiration only
Number of subjects: 118
Study 21300377 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 0
Study 21300377 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 0
Study 21300377 — intervention group
Group type: COMPARATOR
Intervention: Combination of an antipsychotic and an antidepressant
Number of subjects: 0
Study 19342609 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition with thiamine (n=8)
Number of subjects: 15
Study 19342609 — intervention group
Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition without thiamine (n=7)
Number of subjects: 15
Study 17584563 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 313
Study 17584563 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 313